GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » EBITDA Margin %

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) EBITDA Margin % : 22.63% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biocytogen Pharmaceuticals (Beijing) Co's EBITDA for the six months ended in Dec. 2024 was €16.9 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the six months ended in Dec. 2024 was €74.8 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's EBITDA margin for the quarter that ended in Dec. 2024 was 22.63%.

Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
-162.02 -106.65 -69.51 -13.65 30.99

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only -95.69 -43.67 -35.27 1.38 22.63

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin %

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % falls into.


;
;

Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=39.849/128.605
=30.99 %

Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=16.916/74.76
=22.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Biocytogen Pharmaceuticals (Beijing) Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » EBITDA Margin %
Comparable Companies
HKSE:02105 HKSE:02142 HKSE:02256 HKSE:00775 HKSE:06660 HKSE:02480 HKSE:02157 HKSE:06955 HKSE:01672 HKSE:02616 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
02315:Hong Kong
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Website
https://www.biocytogen.com.cn
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines